Compare GMAB & TSCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMAB | TSCO |
|---|---|---|
| Founded | 1999 | 1938 |
| Country | Denmark | United States |
| Employees | 3088 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | RETAIL: Building Materials |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5B | 19.3B |
| IPO Year | N/A | 1996 |
| Metric | GMAB | TSCO |
|---|---|---|
| Price | $27.82 | $31.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 22 |
| Target Price | $39.56 | ★ $53.05 |
| AVG Volume (30 Days) | 1.6M | ★ 12.8M |
| Earning Date | 05-07-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 2.76% |
| EPS Growth | N/A | ★ 0.98 |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | ★ $15,524,046,000.00 |
| Revenue This Year | $17.85 | $7.32 |
| Revenue Next Year | $16.04 | $6.01 |
| P/E Ratio | ★ $1.90 | $102.02 |
| Revenue Growth | N/A | ★ 4.31 |
| 52 Week Low | $20.23 | $28.36 |
| 52 Week High | $35.43 | $63.99 |
| Indicator | GMAB | TSCO |
|---|---|---|
| Relative Strength Index (RSI) | 66.17 | 55.30 |
| Support Level | $25.38 | $29.50 |
| Resistance Level | $28.28 | $56.29 |
| Average True Range (ATR) | 0.59 | 0.89 |
| MACD | 0.33 | 0.38 |
| Stochastic Oscillator | 91.21 | 93.64 |
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,395 of its namesake banners in 49 states, along with 207 Petsense by Tractor Supply stores. Stores are generally concentrated in rural communities rather than urban and suburban areas. In fiscal 2025, revenue consisted primarily of livestock, equine & agriculture (around 30%), companion animal (25%), and seasonal & recreation (around 25%).